Cormorant Asset Management

Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

OnKure Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of innovative cancer therapies. The company specializes in creating less toxic kinase inhibitor drugs and epigenetic therapies, including selective inhibitors of histone deacetylases. Its lead candidate, OKI-179, has demonstrated significant efficacy in preclinical models of hematological and solid tumor cancers, effectively reducing tumor growth both alone and in combination with other targeted therapies. Additionally, OnKure is advancing its HDAC3 selective inhibitor, OKI-422, into preclinical toxicology studies. The company's drug candidates are designed to directly target malignant cells, enhance the effects of small molecule therapies, and optimize the tumor microenvironment for improved checkpoint inhibition, addressing unmet medical needs in cancer treatment.

Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Akura Medical is focused on developing innovative medical devices aimed at improving the process of thrombectomy, specifically through a next-generation device designed for easy use in a single-pass procedure to efficiently remove blood clots. The company specializes in thrombectomy devices and also offers a range of surgical, medical, dental, and veterinary instruments. By providing effective solutions for clot removal, Akura Medical enables healthcare professionals to better address critical needs and treat venous thromboembolism of varying sizes.

OnKure Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of innovative cancer therapies. The company specializes in creating less toxic kinase inhibitor drugs and epigenetic therapies, including selective inhibitors of histone deacetylases. Its lead candidate, OKI-179, has demonstrated significant efficacy in preclinical models of hematological and solid tumor cancers, effectively reducing tumor growth both alone and in combination with other targeted therapies. Additionally, OnKure is advancing its HDAC3 selective inhibitor, OKI-422, into preclinical toxicology studies. The company's drug candidates are designed to directly target malignant cells, enhance the effects of small molecule therapies, and optimize the tumor microenvironment for improved checkpoint inhibition, addressing unmet medical needs in cancer treatment.

BioVentrix, Inc. is a medical device company based in San Ramon, California, that specializes in innovative treatments for congestive heart failure (CHF), particularly in patients with ischemic cardiomyopathy. Founded in 2003, the company has developed the Revivent Myocardial Anchoring System, which utilizes a hybrid closed-chest transcatheter procedure to enhance cardiac function. This device operates by restoring the size and volume of the left ventricle through the implantation of micro-anchoring pairs that effectively exclude scarred myocardium from healthy tissue. BioVentrix aims to provide less invasive, catheter-based solutions to improve patient outcomes and slow the progression of CHF, addressing a critical need in cardiac care.

BiVACOR, Inc., founded in 2008 and based in Houston, Texas, specializes in the design and manufacture of centrifugal heart pumps aimed at replacing the functions of failing hearts. The company has developed an innovative artificial heart-pumping device that features a compact design with a magnetically levitated rotor situated between opposing pump casings. This advanced rotary blood pump technology is engineered to deliver the necessary cardiac output while minimizing the risks of blood-cell damage and clotting. BiVACOR's team comprises skilled engineers, medical specialists, and business executives who collaborate to enhance this groundbreaking technology. The company also maintains an international office in Brisbane, Australia, fostering a strong network to support its mission.

Tioga Cardiovascular is a privately held company under Shifamed LLC, specializing in the development of medical devices for valve replacement in mitral and tricuspid applications. The company is dedicated to creating innovative solutions that simplify procedures and utilize less invasive, transcatheter techniques. By focusing on elegant design and functionality, Tioga Cardiovascular aims to enhance the effectiveness and success of heart surgeries, providing healthcare professionals with advanced tools for treating patients with valvular heart diseases.

JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.

Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative solutions for eye care. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses that address the needs of the intraocular lens replacement market. Atia Vision's technology mimics the natural accommodation of the eye by utilizing the ciliary muscles, which allows for a full range of functional vision restoration for cataract patients. The accommodating intraocular lenses are designed to provide effective vision correction without the need for glasses, thereby improving patient outcomes and enhancing the overall quality of life for individuals with vision impairment.

Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

Akura Medical is focused on developing innovative medical devices aimed at improving the process of thrombectomy, specifically through a next-generation device designed for easy use in a single-pass procedure to efficiently remove blood clots. The company specializes in thrombectomy devices and also offers a range of surgical, medical, dental, and veterinary instruments. By providing effective solutions for clot removal, Akura Medical enables healthcare professionals to better address critical needs and treat venous thromboembolism of varying sizes.

Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

Tioga Cardiovascular is a privately held company under Shifamed LLC, specializing in the development of medical devices for valve replacement in mitral and tricuspid applications. The company is dedicated to creating innovative solutions that simplify procedures and utilize less invasive, transcatheter techniques. By focusing on elegant design and functionality, Tioga Cardiovascular aims to enhance the effectiveness and success of heart surgeries, providing healthcare professionals with advanced tools for treating patients with valvular heart diseases.

Ningbo Jenscare Scientific develops solutions around structural heart disease that include the treatment of the tricuspid valve, mitral valve, aortic valve, and heart failure. The company's contact information is its physical address.

BiVACOR, Inc., founded in 2008 and based in Houston, Texas, specializes in the design and manufacture of centrifugal heart pumps aimed at replacing the functions of failing hearts. The company has developed an innovative artificial heart-pumping device that features a compact design with a magnetically levitated rotor situated between opposing pump casings. This advanced rotary blood pump technology is engineered to deliver the necessary cardiac output while minimizing the risks of blood-cell damage and clotting. BiVACOR's team comprises skilled engineers, medical specialists, and business executives who collaborate to enhance this groundbreaking technology. The company also maintains an international office in Brisbane, Australia, fostering a strong network to support its mission.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

OnKure Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of innovative cancer therapies. The company specializes in creating less toxic kinase inhibitor drugs and epigenetic therapies, including selective inhibitors of histone deacetylases. Its lead candidate, OKI-179, has demonstrated significant efficacy in preclinical models of hematological and solid tumor cancers, effectively reducing tumor growth both alone and in combination with other targeted therapies. Additionally, OnKure is advancing its HDAC3 selective inhibitor, OKI-422, into preclinical toxicology studies. The company's drug candidates are designed to directly target malignant cells, enhance the effects of small molecule therapies, and optimize the tumor microenvironment for improved checkpoint inhibition, addressing unmet medical needs in cancer treatment.

Elevation Oncology, Inc. is a biotechnology company dedicated to developing precision medicines for patients with genomically defined cancers. The company focuses on creating targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. Its lead drug candidate, seribantumab, targets neuregulin-1 (NRG1) fusions, which are rare genomic alterations that can be treated through targeted HER3 inhibition. Currently, seribantumab is undergoing clinical testing in the Phase 2 CRESTONE study, which evaluates its efficacy in patients with solid tumors of any origin that harbor NRG1 fusions. Founded in 2019 and based in New York, Elevation Oncology aims to make genomic tests actionable by selectively developing drugs that address these specific alterations in cancer patients.

Aerovate Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to developing innovative treatments for patients with rare cardiopulmonary diseases. The company's primary focus is on AV-101, a proprietary inhaled dry powder formulation of the drug imatinib, designed specifically for the treatment of pulmonary arterial hypertension (PAH). This formulation enables targeted delivery of the medication directly to affected lung tissues, thereby minimizing systemic side effects commonly associated with traditional treatments. Established in 2018, Aerovate aims to provide meaningful improvements in the lives of those suffering from these serious conditions.

New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for cancers driven by the RAS/MAPK pathway. Founded in 2018, the company utilizes its artificial intelligence-driven oncology pattern recognition algorithm (OPRA) to analyze extensive datasets and uncover novel tumor biology, which aids in the identification of key oncogenes. Erasca's drug development pipeline includes Naporafenib, a pan-RAF inhibitor with potential applications in NRAS mutant melanoma and other RAS/MAPK pathway-driven tumors, as well as ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor. The company aims to provide precision oncology options through collaborations with academic and biopharmaceutical partners, ultimately seeking to offer innovative treatment solutions for patients.

Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.

Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.

Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative solutions for eye care. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses that address the needs of the intraocular lens replacement market. Atia Vision's technology mimics the natural accommodation of the eye by utilizing the ciliary muscles, which allows for a full range of functional vision restoration for cataract patients. The accommodating intraocular lenses are designed to provide effective vision correction without the need for glasses, thereby improving patient outcomes and enhancing the overall quality of life for individuals with vision impairment.

NuVera Medical, Inc. is a privately held company based in Campbell, California, specializing in the development of an innovative imaging platform designed for complex cardiovascular procedures. Established in 2016, the company utilizes advanced 4D ultrasound technology to enhance intracardiac echocardiography. This platform enables healthcare specialists, particularly cardiologists, to perform transcatheter cardiac interventions by providing real-time visualization of heart chambers. This capability supports informed decision-making during procedures, ultimately aiming to improve patient outcomes in cardiovascular care. NuVera Medical operates under the portfolio of Shifamed, LLC.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for cancers driven by the RAS/MAPK pathway. Founded in 2018, the company utilizes its artificial intelligence-driven oncology pattern recognition algorithm (OPRA) to analyze extensive datasets and uncover novel tumor biology, which aids in the identification of key oncogenes. Erasca's drug development pipeline includes Naporafenib, a pan-RAF inhibitor with potential applications in NRAS mutant melanoma and other RAS/MAPK pathway-driven tumors, as well as ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor. The company aims to provide precision oncology options through collaborations with academic and biopharmaceutical partners, ultimately seeking to offer innovative treatment solutions for patients.

Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative solutions for eye care. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses that address the needs of the intraocular lens replacement market. Atia Vision's technology mimics the natural accommodation of the eye by utilizing the ciliary muscles, which allows for a full range of functional vision restoration for cataract patients. The accommodating intraocular lenses are designed to provide effective vision correction without the need for glasses, thereby improving patient outcomes and enhancing the overall quality of life for individuals with vision impairment.

Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.

Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.

Axonics Modulation Technologies, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation (SNM) systems, catering to both domestic and international markets. The company’s SNM systems are designed to address conditions such as overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its innovative rechargeable SNM System delivers mild electrical pulses to the sacral nerve, aiming to restore normal communication between the brain and the bladder and bowel to alleviate associated symptoms. Originally incorporated as American Restorative Medicine, Inc. in 2012, the company rebranded as Axonics Modulation Technologies, Inc. in August 2013 and is headquartered in Irvine, California.

Axonics Modulation Technologies, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation (SNM) systems, catering to both domestic and international markets. The company’s SNM systems are designed to address conditions such as overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its innovative rechargeable SNM System delivers mild electrical pulses to the sacral nerve, aiming to restore normal communication between the brain and the bladder and bowel to alleviate associated symptoms. Originally incorporated as American Restorative Medicine, Inc. in 2012, the company rebranded as Axonics Modulation Technologies, Inc. in August 2013 and is headquartered in Irvine, California.

NuVera Medical, Inc. is a privately held company based in Campbell, California, specializing in the development of an innovative imaging platform designed for complex cardiovascular procedures. Established in 2016, the company utilizes advanced 4D ultrasound technology to enhance intracardiac echocardiography. This platform enables healthcare specialists, particularly cardiologists, to perform transcatheter cardiac interventions by providing real-time visualization of heart chambers. This capability supports informed decision-making during procedures, ultimately aiming to improve patient outcomes in cardiovascular care. NuVera Medical operates under the portfolio of Shifamed, LLC.

Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.

Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

Axonics Modulation Technologies, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation (SNM) systems, catering to both domestic and international markets. The company’s SNM systems are designed to address conditions such as overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its innovative rechargeable SNM System delivers mild electrical pulses to the sacral nerve, aiming to restore normal communication between the brain and the bladder and bowel to alleviate associated symptoms. Originally incorporated as American Restorative Medicine, Inc. in 2012, the company rebranded as Axonics Modulation Technologies, Inc. in August 2013 and is headquartered in Irvine, California.

Ovid Therapeutics Inc. is a biopharmaceutical company based in New York, focused on developing innovative therapies for patients with neurological disorders, particularly rare diseases. Founded in 2014, the company is advancing a promising pipeline of drug candidates aimed at treating conditions such as angelman syndrome and fragile X syndrome. Its lead candidate, OV101, is in Phase III clinical trials for angelman syndrome and has completed Phase II trials for fragile X syndrome. Additionally, Ovid is developing OV935, currently in Phase II trials for cyclin-dependent kinase-like 5 deficiency disorder and Dravet syndrome. The company is also researching OV329 for infantile spasms and OV881 as a microRNA gene therapy for angelman syndrome. Ovid Therapeutics has established collaborations and licensing agreements with various pharmaceutical and research organizations to enhance its development efforts. The company's commitment to addressing unmet medical needs is underpinned by strong intellectual property and a focus on safe, effective treatments for patients facing challenging neurological conditions.